Sobi’s Dova Pharmaceutical Reports Results of an Online Survey Highlighting Disease Burden and Impact for Patients with Immune Thrombocytopenia

Sobi’s Dova Pharmaceutical Reports Results of an Online Survey Highlighting Disease Burden and Impact for Patients with Immune Thrombocytopenia

Shots:

  • The online survey assesses 76 patients from the Platelet Disorder Support Association that has been diagnosed with ITP, prior treated with at least one therapy. The 30-45-min online survey is about demographics, diagnosis experience, symptoms, disease management and treatment
  • Results: 58% demonstrated ITP-related fatigue interfered with their work, family, or social life; prior to-/ post-treatment, 35%/39% & 13%/16% reported fatigue daily & twice a wk.; Platelet count at diagnosis: < 10 x 109/L (47%) and 10 – 30 x 109/L (27%), at time of survey: < 30 x 109/L (4.62 %) and > 100 x 109/L (47.69%) respectively
  • The survey demonstrates the complexity of ITP and the effects of fatigue, bleeding and treatment on the lives of the patients. The survey reported that 59% reported bleeding does not interfere with their work, family or social life

Click here to­ read full press release/ article | Ref: Sobi | Image: Pharmaceutical Technology